Lipoprotein(a) Foundation: Did You Know That 63 Million Americans Have a High Risk of Inherited Cardiovascular Disease and May Not Know It?

Lp(a) Foundation Issues Heart Month Infographic to Raise Awareness that a Simple Blood Test Could be the First Step in Preventing up to 120,000 Cardiovascular Events Every Year

(Graphic: Business Wire)

SAN CARLOS, Calif.--()--Lipoprotein(a) Foundation:



Lipoprotein(a), also known as Lp(a), is currently the strongest monogenetic risk factor for coronary heart disease and aortic stenosis.2 Unfortunately, for some people, the first sign of disease is a heart attack or stroke.

• It is estimated that 1 in 5 people globally have inherited high Lp(a): 63million in the U.S.4

• If an adult has high Lp(a), there is at least a 50% chance of their children inheriting it.

• Poor lifestyle habits do not contribute to high Lipoprotein(a). Diet and exercise has little to no impact on lowering Lp(a).

• In the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults, elevated levels of Lp(a) are associated with an increased risk for a premature cardiovascular event. In 2010, the European Atherosclerosis Society recommended screening for elevated Lp(a) as a priority for reducing cardiovascular risk.



Up to 120,000 Lp(a) Related Cardiovascular Events Go Undetected Each Year1; Simple Blood Test Could be First Step in Preventing

• Lp(a) concentrations can be measured by a simple blood test, but it is not included in most standard lipid panel tests that check cholesterol levels. 1

• A study recently published in JACC shows that the current cholesterol guidelines miss 8% of people who have a cardiovascular event whose only risk factor is high Lp(a).1

• When you consider 1.5 million cardiovascular events each year in the U.S. 5, that equals 120,000 potentially preventable events with proactive screening for Lp(a)1.



What Can People Do if They Have a Family History of Cardiovascular Disease?

• Use the Family Tree Sheet to map out your family history of cardiovascular disease.

• Talk to your doctor about Lp(a) testing to get an accurate risk assessment and lower controllable risk factors until there is a therapy for high Lp(a).

• Support patient advocacy to find a therapy and advocate for more research for high Lp(a) at



The following cardiovascular event survivors and cardiovascular disease experts are available to discuss hereditary risks of cardiovascular disease associated with Lp(a):

• Sandra Revill Tremulis, Calif-based survivor and founder of Lipoprotein(a) Foundation

• Lp(a) Foundation Patient Advocates / Survivors in Cities around the Nation

• Sotirios (Sam) Tsimikas, MD, Director, Vascular Medicine, University of California San Diego; Deputy Editor of the Journal of the American College of Cardiology and Associate Editor of JACC Cardiovascular Interventions

• Amit Khera, MD, MSc, Director of the Preventive Cardiology Section, UT Southwestern Medical Center, Dallas, TX

1 Mortensen M, MD, PHD, Afzal S, MD, PHD et al. Primary Prevention with Statins. ACC/AHA Risk-Based Approach Versus Trial-Based Approaches to Guide Statin Therapy. Guide Statin Therapy. JACC.
2 CARDIoGRAMplusC4D Consortium, Deloukas P et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2013 Jan;45(1):25-33

3 Thanassoulis G. et al. Genetic Associations with Valvular calcification and aortic stenosis. N Engl J Med. 2013 Feb 7;368(6):503-12. doi: 10.1056/NEJMoa1109034

4 Nordestgaard F., Chapman J, et al. Lipoprotein(a) as a cardiovascular risk factor current status. European Heart J. 2010;31,2844-2853

5 CDC reference:


Lipoprotein(a) Foundation:
Chris K. Joseph, 510-435-4031

Release Summary

Lipoprotein(A) Foundation, Lp(a), Issues Heart Month Infographic to Raise Awareness that a Simple Blood Test Could be the First Step in Preventing up to 120,000 Cardiovascular Events Every Year


Lipoprotein(a) Foundation:
Chris K. Joseph, 510-435-4031